Lire la suite…<\/a><\/p>\n\n\n\n<\/p>\n","protected":false},"excerpt":{"rendered":"
Glycovax Pharma a re\u00e7u une licence du Conseil national de recherches du Canada pour d\u00e9velopper un vaccin glycoconjugu\u00e9 semi-synth\u00e9tique ciblant Pseudomonas aeruginosa (Pa), une bact\u00e9rie responsable d\u2019infections nosocomiales graves, particuli\u00e8rement mortelles chez les personnes atteintes de fibrose kystique. Ce projet r\u00e9pond \u00e0 une priorit\u00e9 de l\u2019OMS en raison de la forte r\u00e9sistance aux antibiotiques de…<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[95],"tags":[94],"class_list":["post-2529","post","type-post","status-publish","format-standard","hentry","category-nouvelles","tag-featured-fr"],"acf":[],"yoast_head":"\n
Vaccin contre Pseudomonas aeruginosa | Glycovax obtient une licence du CNRC<\/title>\n<meta name=\"description\" content=\"Glycovax Pharma obtient une licence du CNRC pour d\u00e9velopper un vaccin semi-synth\u00e9tique contre Pseudomonas aeruginosa, une bact\u00e9rie nosocomiale prioritaire selon l\u2019OMS.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/glycovax.com\/fr\/glycovax-pharma-obtient-une-licence-du-cnrc-pour-developper-un-vaccin-contre-pseudomonas-aeruginosa\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Vaccin contre Pseudomonas aeruginosa | Glycovax obtient une licence du CNRC\" \/>\n<meta property=\"og:description\" content=\"Glycovax Pharma obtient une licence du CNRC pour d\u00e9velopper un vaccin semi-synth\u00e9tique contre Pseudomonas aeruginosa, une bact\u00e9rie nosocomiale prioritaire selon l\u2019OMS.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/glycovax.com\/fr\/glycovax-pharma-obtient-une-licence-du-cnrc-pour-developper-un-vaccin-contre-pseudomonas-aeruginosa\/\" \/>\n<meta property=\"og:site_name\" content=\"Glycovax Pharma\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-18T13:00:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-08-18T18:24:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/glycovax.com\/wp-content\/uploads\/2025\/08\/glycovax-7i9a7324-visuel-FR-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2048\" \/>\n\t<meta property=\"og:image:height\" content=\"1152\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Claude Dagenais\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Claude Dagenais\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/glycovax.com\\\/fr\\\/glycovax-pharma-obtient-une-licence-du-cnrc-pour-developper-un-vaccin-contre-pseudomonas-aeruginosa\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/glycovax.com\\\/fr\\\/glycovax-pharma-obtient-une-licence-du-cnrc-pour-developper-un-vaccin-contre-pseudomonas-aeruginosa\\\/\"},\"author\":{\"name\":\"Claude Dagenais\",\"@id\":\"https:\\\/\\\/glycovax.com\\\/fr\\\/#\\\/schema\\\/person\\\/791c61a78825c9dc04135e2ceaca3883\"},\"headline\":\"Glycovax Pharma obtient une licence du CNRC pour d\u00e9velopper un vaccin contre Pseudomonas aeruginosa\",\"datePublished\":\"2025-08-18T13:00:00+00:00\",\"dateModified\":\"2025-08-18T18:24:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/glycovax.com\\\/fr\\\/glycovax-pharma-obtient-une-licence-du-cnrc-pour-developper-un-vaccin-contre-pseudomonas-aeruginosa\\\/\"},\"wordCount\":90,\"publisher\":{\"@id\":\"https:\\\/\\\/glycovax.com\\\/fr\\\/#organization\"},\"keywords\":[\"Featured\"],\"articleSection\":[\"Nouvelles\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/glycovax.com\\\/fr\\\/glycovax-pharma-obtient-une-licence-du-cnrc-pour-developper-un-vaccin-contre-pseudomonas-aeruginosa\\\/\",\"url\":\"https:\\\/\\\/glycovax.com\\\/fr\\\/glycovax-pharma-obtient-une-licence-du-cnrc-pour-developper-un-vaccin-contre-pseudomonas-aeruginosa\\\/\",\"name\":\"Vaccin contre Pseudomonas aeruginosa | Glycovax obtient une licence du CNRC\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/glycovax.com\\\/fr\\\/#website\"},\"datePublished\":\"2025-08-18T13:00:00+00:00\",\"dateModified\":\"2025-08-18T18:24:07+00:00\",\"description\":\"Glycovax Pharma obtient une licence du CNRC pour d\u00e9velopper un vaccin semi-synth\u00e9tique contre Pseudomonas aeruginosa, une bact\u00e9rie nosocomiale prioritaire selon l\u2019OMS.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/glycovax.com\\\/fr\\\/glycovax-pharma-obtient-une-licence-du-cnrc-pour-developper-un-vaccin-contre-pseudomonas-aeruginosa\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/glycovax.com\\\/fr\\\/glycovax-pharma-obtient-une-licence-du-cnrc-pour-developper-un-vaccin-contre-pseudomonas-aeruginosa\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/glycovax.com\\\/fr\\\/glycovax-pharma-obtient-une-licence-du-cnrc-pour-developper-un-vaccin-contre-pseudomonas-aeruginosa\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/glycovax.com\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Glycovax Pharma obtient une licence du CNRC pour d\u00e9velopper un vaccin contre Pseudomonas aeruginosa\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/glycovax.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/glycovax.com\\\/fr\\\/\",\"name\":\"Glycovax Pharma\",\"description\":\"Saving millions of lives by using the power of advanced medical nanotechnology.\",\"publisher\":{\"@id\":\"https:\\\/\\\/glycovax.com\\\/fr\\\/#organization\"},\"alternateName\":\"Glycovax\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/glycovax.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/glycovax.com\\\/fr\\\/#organization\",\"name\":\"Glycovax Pharma\",\"alternateName\":\"Glycovax\",\"url\":\"https:\\\/\\\/glycovax.com\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/glycovax.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/glycovax.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/Glycovax-Pharma-carre.png\",\"contentUrl\":\"https:\\\/\\\/glycovax.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/Glycovax-Pharma-carre.png\",\"width\":1200,\"height\":1200,\"caption\":\"Glycovax Pharma\"},\"image\":{\"@id\":\"https:\\\/\\\/glycovax.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/glycovax.com\\\/fr\\\/#\\\/schema\\\/person\\\/791c61a78825c9dc04135e2ceaca3883\",\"name\":\"Claude Dagenais\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/f4b8cea30a420f348ecee86e20e8aa60d5506584eaad9180873c59b61f2260fe?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/f4b8cea30a420f348ecee86e20e8aa60d5506584eaad9180873c59b61f2260fe?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/f4b8cea30a420f348ecee86e20e8aa60d5506584eaad9180873c59b61f2260fe?s=96&d=mm&r=g\",\"caption\":\"Claude Dagenais\"},\"sameAs\":[\"https:\\\/\\\/twohumans.com\\\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Vaccin contre Pseudomonas aeruginosa | Glycovax obtient une licence du CNRC","description":"Glycovax Pharma obtient une licence du CNRC pour d\u00e9velopper un vaccin semi-synth\u00e9tique contre Pseudomonas aeruginosa, une bact\u00e9rie nosocomiale prioritaire selon l\u2019OMS.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/glycovax.com\/fr\/glycovax-pharma-obtient-une-licence-du-cnrc-pour-developper-un-vaccin-contre-pseudomonas-aeruginosa\/","og_locale":"fr_FR","og_type":"article","og_title":"Vaccin contre Pseudomonas aeruginosa | Glycovax obtient une licence du CNRC","og_description":"Glycovax Pharma obtient une licence du CNRC pour d\u00e9velopper un vaccin semi-synth\u00e9tique contre Pseudomonas aeruginosa, une bact\u00e9rie nosocomiale prioritaire selon l\u2019OMS.","og_url":"https:\/\/glycovax.com\/fr\/glycovax-pharma-obtient-une-licence-du-cnrc-pour-developper-un-vaccin-contre-pseudomonas-aeruginosa\/","og_site_name":"Glycovax Pharma","article_published_time":"2025-08-18T13:00:00+00:00","article_modified_time":"2025-08-18T18:24:07+00:00","og_image":[{"width":2048,"height":1152,"url":"https:\/\/glycovax.com\/wp-content\/uploads\/2025\/08\/glycovax-7i9a7324-visuel-FR-scaled.jpg","type":"image\/jpeg"}],"author":"Claude Dagenais","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Claude Dagenais","Dur\u00e9e de lecture estim\u00e9e":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/glycovax.com\/fr\/glycovax-pharma-obtient-une-licence-du-cnrc-pour-developper-un-vaccin-contre-pseudomonas-aeruginosa\/#article","isPartOf":{"@id":"https:\/\/glycovax.com\/fr\/glycovax-pharma-obtient-une-licence-du-cnrc-pour-developper-un-vaccin-contre-pseudomonas-aeruginosa\/"},"author":{"name":"Claude Dagenais","@id":"https:\/\/glycovax.com\/fr\/#\/schema\/person\/791c61a78825c9dc04135e2ceaca3883"},"headline":"Glycovax Pharma obtient une licence du CNRC pour d\u00e9velopper un vaccin contre Pseudomonas aeruginosa","datePublished":"2025-08-18T13:00:00+00:00","dateModified":"2025-08-18T18:24:07+00:00","mainEntityOfPage":{"@id":"https:\/\/glycovax.com\/fr\/glycovax-pharma-obtient-une-licence-du-cnrc-pour-developper-un-vaccin-contre-pseudomonas-aeruginosa\/"},"wordCount":90,"publisher":{"@id":"https:\/\/glycovax.com\/fr\/#organization"},"keywords":["Featured"],"articleSection":["Nouvelles"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/glycovax.com\/fr\/glycovax-pharma-obtient-une-licence-du-cnrc-pour-developper-un-vaccin-contre-pseudomonas-aeruginosa\/","url":"https:\/\/glycovax.com\/fr\/glycovax-pharma-obtient-une-licence-du-cnrc-pour-developper-un-vaccin-contre-pseudomonas-aeruginosa\/","name":"Vaccin contre Pseudomonas aeruginosa | Glycovax obtient une licence du CNRC","isPartOf":{"@id":"https:\/\/glycovax.com\/fr\/#website"},"datePublished":"2025-08-18T13:00:00+00:00","dateModified":"2025-08-18T18:24:07+00:00","description":"Glycovax Pharma obtient une licence du CNRC pour d\u00e9velopper un vaccin semi-synth\u00e9tique contre Pseudomonas aeruginosa, une bact\u00e9rie nosocomiale prioritaire selon l\u2019OMS.","breadcrumb":{"@id":"https:\/\/glycovax.com\/fr\/glycovax-pharma-obtient-une-licence-du-cnrc-pour-developper-un-vaccin-contre-pseudomonas-aeruginosa\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/glycovax.com\/fr\/glycovax-pharma-obtient-une-licence-du-cnrc-pour-developper-un-vaccin-contre-pseudomonas-aeruginosa\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/glycovax.com\/fr\/glycovax-pharma-obtient-une-licence-du-cnrc-pour-developper-un-vaccin-contre-pseudomonas-aeruginosa\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/glycovax.com\/fr\/"},{"@type":"ListItem","position":2,"name":"Glycovax Pharma obtient une licence du CNRC pour d\u00e9velopper un vaccin contre Pseudomonas aeruginosa"}]},{"@type":"WebSite","@id":"https:\/\/glycovax.com\/fr\/#website","url":"https:\/\/glycovax.com\/fr\/","name":"Glycovax Pharma","description":"Saving millions of lives by using the power of advanced medical nanotechnology.","publisher":{"@id":"https:\/\/glycovax.com\/fr\/#organization"},"alternateName":"Glycovax","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/glycovax.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/glycovax.com\/fr\/#organization","name":"Glycovax Pharma","alternateName":"Glycovax","url":"https:\/\/glycovax.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/glycovax.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/glycovax.com\/wp-content\/uploads\/2025\/04\/Glycovax-Pharma-carre.png","contentUrl":"https:\/\/glycovax.com\/wp-content\/uploads\/2025\/04\/Glycovax-Pharma-carre.png","width":1200,"height":1200,"caption":"Glycovax Pharma"},"image":{"@id":"https:\/\/glycovax.com\/fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/glycovax.com\/fr\/#\/schema\/person\/791c61a78825c9dc04135e2ceaca3883","name":"Claude Dagenais","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/f4b8cea30a420f348ecee86e20e8aa60d5506584eaad9180873c59b61f2260fe?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/f4b8cea30a420f348ecee86e20e8aa60d5506584eaad9180873c59b61f2260fe?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/f4b8cea30a420f348ecee86e20e8aa60d5506584eaad9180873c59b61f2260fe?s=96&d=mm&r=g","caption":"Claude Dagenais"},"sameAs":["https:\/\/twohumans.com\/"]}]}},"_links":{"self":[{"href":"https:\/\/glycovax.com\/fr\/wp-json\/wp\/v2\/posts\/2529","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/glycovax.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/glycovax.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/glycovax.com\/fr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/glycovax.com\/fr\/wp-json\/wp\/v2\/comments?post=2529"}],"version-history":[{"count":4,"href":"https:\/\/glycovax.com\/fr\/wp-json\/wp\/v2\/posts\/2529\/revisions"}],"predecessor-version":[{"id":2547,"href":"https:\/\/glycovax.com\/fr\/wp-json\/wp\/v2\/posts\/2529\/revisions\/2547"}],"wp:attachment":[{"href":"https:\/\/glycovax.com\/fr\/wp-json\/wp\/v2\/media?parent=2529"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/glycovax.com\/fr\/wp-json\/wp\/v2\/categories?post=2529"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/glycovax.com\/fr\/wp-json\/wp\/v2\/tags?post=2529"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}